Application of PLGA nano/microparticle delivery systems for immunomodulation and prevention of allotransplant rejection

References

• Watson C, Dark J. Organ transplantation: historical perspective and current practice. Br J Anaesth. 2012;108(suppl_1):i29–i42.
   PubMedGoogle Scholar
• Quinby WC. The function of the kidney when deprived of its nerves. J Exp Med. 1916;23(4):535.
   PubMedGoogle Scholar
• Simonsen M, Buemann J, Gammeltoft A, et al. Biological incompatibility in kidney transplantation in dogs: I. Experimental and morphological investigations. Acta Pathologica Microbiologica Scand. 1953;32(1):1–35.
   PubMedGoogle Scholar
• Murray J, Lang S, Miller B, et al. Prolonged functional survival of renal autotransplants in the dog. Surg Gynecology Obstetrics. 1956;103(1):15.
   PubMedGoogle Scholar
• Hume DM, Merrill JP, Miller BF, et al. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest. 1955;34(2):327–382.
   PubMed Web of Science ®Google Scholar
• Ratcliffe P, Dudley C, Higgins R, et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet. 1996;348(9028):643–648.
   PubMed Web of Science ®Google Scholar
• Calne R, Williams R. Liver transplantation in man—I, observations on technique and organization in five cases. Br Med J. 1968;4(5630):535–540.
   PubMed Web of Science ®Google Scholar
• Calne R, Evans D, Herbertson B, et al. Survival after renal transplantation in man: an interim report on 54 consecutive transplants. Br Med J. 1968;2(5602):404.
   PubMedGoogle Scholar
• Lower RR, Stofer RC, Shumway NE. A study of pulmonary valve autotransplantation. Surgery. 1960;48(6):1090–1100.
   PubMed Web of Science ®Google Scholar
• Coulson AS, Zeitman VH, Stinson EB, et al. Immunodepressive serum treatment of acute heart transplant rejection. Br Med J. 1976;1(6012):749.
   PubMedGoogle Scholar
• Allan JS, Madsen JC. Recent advances in the immunology of chronic rejection. Curr Opin Nephrol Hypertens. 2002;11(3):315–321.
   PubMed Web of Science ®Google Scholar
• Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353(9158):1083–1091.
   PubMed Web of Science ®Google Scholar
• Timm S, Otto C, Begrich D, et al. Immunogenicity of parathyroid allografts in the rat: immunosuppressive dosages effective in passenger leukocyte-rich small bowel transplants are not effective in parathyroid gland transplants with few passenger leukocytes. Langenbecks Arch Surg. 2004;389(1):46–52.
   PubMed Web of Science ®Google Scholar
• Kerman RH, Orosz CC, Lorber MI. Clinical relevance of anti-HLA antibodies pre and post transplant. Am J Med Sci. 1997;313(5):275–278.
   PubMed Web of Science ®Google Scholar
• Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplantation Rev. 2009;23(1):34–46.
   Google Scholar
• Rocha PN, Plumb TJ, Crowley SD, et al. Effector mechanisms in transplant rejection. Immunol Rev. 2003;196(1):51–64.
   PubMed Web of Science ®Google Scholar
• Libby P, Pober JS. Chronic rejection. Immunity. 2001;14(4):387–397.
   PubMed Web of Science ®Google Scholar
• Racusen LC. Immunopathology of organ transplantation. Springer Semin Immunopathol 2003;25:141–165.
   Google Scholar
• Fairchild RL. The Yin and Yang of IFN‐γ in Allograft Rejection. Am J Transplant. 2003;3(8):913–914.
   PubMed Web of Science ®Google Scholar
• Chapman J. Optimizing the long-term outcome of renal transplants: opportunities created by sirolimus. Transplant proc. 2003;35(S3):67S–72S.
   Google Scholar
• Savikko J, von Willebrand E, Häyry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation. 2003;76(3):455–458.
   PubMed Web of Science ®Google Scholar
• Toungouz M, Donckier V, Goldman M. Tolerance induction in clinical transplantation: the pending questions. Transplantation. 2003;75(9):58S–60S.
   PubMed Web of Science ®Google Scholar
• Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol. 2012;12(6):417.
   PubMed Web of Science ®Google Scholar
• Brown K, Sacks S, Wong W. Coexpression of donor peptide/recipient MHC complex and intact donor MHC: evidence for a link between the direct and indirect pathways. Am J Transplant. 2011;11(4):826–831.
   PubMed Web of Science ®Google Scholar
• Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today. 1994;15(1):32–38.
   PubMedGoogle Scholar
• Illigens BM, Yamada A, Fedoseyeva EV, et al. The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol. 2002;63(10):912–925.
   PubMed Web of Science ®Google Scholar
• Herrera OB, Golshayan D, Tibbott R, et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol. 2004;173(8):4828–4837.
   PubMed Web of Science ®Google Scholar
• Afzali B, Lechler R, Hernandez‐Fuentes M. Allorecognition and the alloresponse: clinical implications. Tissue Antigens. 2007;69(6):545–556.
   PubMedGoogle Scholar
• Italia JL, Bhardwaj V, Kumar MR. Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. Drug Discov Today. 2006;11(17–18):846–854.
   PubMed Web of Science ®Google Scholar
• Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. J Antibiot (Tokyo). 1987;40(9):1256–1265.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508.
   PubMed Web of Science ®Google Scholar
• Ayres R, Dousset B, Wixon S, et al. Peripheral neurotoxicity with tacrolimus. Lancet. 1994;343(8901):862–863.
   PubMed Web of Science ®Google Scholar
• Platz K-P, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation. 1994;58(2):170–178.
   PubMed Web of Science ®Google Scholar
• Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001;59(1):3–16.
   PubMed Web of Science ®Google Scholar
• R, Turnquist HR, Taner T, et al. Use of rapamycin in the induction of tolerogenic dendritic cells. In: Dendritic Cells. Springer, 2009. p. 215–232.
   Google Scholar
• Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood. 2003;101(11):4457–4463.
   PubMed Web of Science ®Google Scholar
• Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178(11):7018–7031.
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Balmert SC, Raimondi G, et al. Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells. J Control Release. 2012;159(1):78–84.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes. 2006;55(1):40–49.
   PubMed Web of Science ®Google Scholar
• Strauss L, Whiteside TL, Knights A, et al. Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with rapamycin. J Immunol. 2007;178(1):320–329.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Stabilini A, Migliavacca B, et al. Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177(12):8338–8347.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Stabilini A, Roncarolo M-G. Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells. Blood. 2005;105(12):4743–4748.
   PubMed Web of Science ®Google Scholar
• Lee H, Huh K, Kim Y, et al., editors. Sirolimus-induced pneumonitis after renal transplantation: a single-center experience. Transplant proc. 2012;44(1):161–163.
   Google Scholar
• Pinsky B, Takemoto S, Lentine K, et al. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant. 2009;9(11):2597–2606.
   PubMed Web of Science ®Google Scholar
• Dew MA, DiMartini AF, Dabbs ADV, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83(7):858–873.
   PubMed Web of Science ®Google Scholar
• Bosma OH, Vermeulen KM, Verschuuren EA, et al. Adherence to immunosuppression in adult lung transplant recipients: prevalence and risk factors. J Heart Lung Transplant. 2011;30(11):1275–1280.
   PubMed Web of Science ®Google Scholar
• Fisher JD, Acharya AP, Little SR. Micro and nanoparticle drug delivery systems for preventing allotransplant rejection. Clin Immunol. 2015;160(1):24–35.
   PubMed Web of Science ®Google Scholar
• Ruiz P, Maldonado P, Hidalgo Y, et al. Transplant tolerance: new insights and strategies for long-term allograft acceptance. Clin Dev Immunol. 2013;210506.
   PubMedGoogle Scholar
• Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature. 2009;462(7272):449.
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522.
   PubMed Web of Science ®Google Scholar
• Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng. 2007;96(2):203–209.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ghassemi AH, Hennink WE, et al. The microclimate pH in poly (D, L-lactide-co-hydroxymethyl glycolide) microspheres during biodegradation. Biomaterials. 2012;33(30):7584–7593.
   PubMed Web of Science ®Google Scholar
• Stanković M, Tomar J, Hiemstra C, et al. Tailored protein release from biodegradable poly (ε-caprolactone-PEG)-b-poly (ε-caprolactone) multiblock-copolymer implants. Eur J Pharm Biopharm. 2014;87(2):329–337.
   PubMed Web of Science ®Google Scholar
• Balmert SC, Little SR. Biomimetic delivery with micro‐and nanoparticles. Adv Mater. 2012;24(28):3757–3778.
   PubMed Web of Science ®Google Scholar
• Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res. 2008;25(8):1815–1821.
   PubMed Web of Science ®Google Scholar
• Moon JJ, Huang B, Irvine DJ. Engineering nano‐and microparticles to tune immunity. Adv Mater. 2012;24(28):3724–3746.
   PubMed Web of Science ®Google Scholar
• Ghassemi A, Van Steenbergen M, Talsma H, et al. Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly (lactic-co-hydroxymethyl glycolic acid). J Control Release. 2009;138(1):57–63.
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Gremse F, Theek B, et al. Noninvasive optical imaging of nanomedicine biodistribution. ACS Nano. 2012;7(1):252–262.
   PubMed Web of Science ®Google Scholar
• Hou Y, Liu Y, Chen Z, et al. Manufacture of IRDye800CW-coupled Fe 3 O 4 nanoparticles and their applications in cell labeling and in vivo imaging. J Nanobiotechnology. 2010;8(1):25.
   PubMedGoogle Scholar
• Sánchez A, Seoane R, Quireza O, et al. In vivo study of the tissue distribution and immunosuppressive response of cyclosporin a-loaded polyester micro-and nanospheres. Drug Deliv. 1995;2(1):21–28.
   Google Scholar
• Sanchez A, Alonso MJ. Poly (D, L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood. Eur J Pharm Biopharm. 1995;41(1):31–37.
   Web of Science ®Google Scholar
• Yoshikawa H, Seebach S. Lymphotropic delivery of cyclosporin A by intramuscular injection of biodegradable microspheres in mice. Biol Pharm Bull. 1996;19(11):1527–1529.
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Uno T, Yamamoto H, et al. Pharmacokinetic and immunosuppressive effects of tacrolimus‐loaded biodegradable microspheres. Liver Transpl. 2004;10(3):392–396.
   PubMed Web of Science ®Google Scholar
• Wang Q, Uno T, Miyamoto Y, et al. Biodegradable microsphere‐loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. Am J Transplant. 2004;4(5):721–727.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Yamamoto H, Takeuchi H, et al. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther. 2005;315(1):196–202.
   PubMed Web of Science ®Google Scholar
• Meer Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int J Pharm. 2006;316(1–2):138–143.
   PubMedGoogle Scholar
• Lamprecht A, Yamamoto H, Takeuchi H, et al. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J Control Release. 2005;104(2):337–346.
   PubMed Web of Science ®Google Scholar
• Glowacki AJ, Gottardi R, Yoshizawa S, et al. Strategies to direct the enrichment, expansion, and recruitment of regulatory cells for the treatment of disease. Ann Biomed Eng. 2015;43(3):593–602.
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Raimondi G, Thomson AW, et al. Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release. 2009;133(3):191–197.
   PubMed Web of Science ®Google Scholar
• Haddadi A, Elamanchili P, Lavasanifar A, et al. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J Biomed Mater Res A. 2008;84(4):885–898.
   PubMedGoogle Scholar
• Das S, Haddadi A, Veniamin S, et al. Delivery of rapamycin‐loaded nanoparticle down regulates ICAM‐1 expression and maintains an immunosuppressive profile in human CD34+ progenitor‐derived dendritic cells. J Biomed Mater Res A. 2008;85(4):983–992.
   PubMedGoogle Scholar
• Shirali A, Look M, Du W, et al. Nanoparticle delivery of mycophenolic acid upregulates PD‐L1 on dendritic cells to prolong murine allograft survival. Am J Transplant. 2011;11(12):2582–2592.
   PubMed Web of Science ®Google Scholar
• Metcalfe SM, Watson TJ, Shurey S, et al. Leukemia inhibitory factor is linked to regulatory transplantation tolerance. Transplantation. 2005;79(6):726–730.
   PubMed Web of Science ®Google Scholar
• Gao W, Thompson L, Zhou Q, et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009;8(9):1444–1450.
   PubMed Web of Science ®Google Scholar
• Park J, Gao W, Whiston R, et al. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol Pharm. 2010;8(1):143–152.
   PubMedGoogle Scholar
• Dong H, Fahmy TM, Metcalfe SM, et al. Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice. PloS One. 2012;7(12):e50265.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942.
   PubMed Web of Science ®Google Scholar
• Lee I, Wang L, Wells AD, et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med. 2005;201(7):1037–1044.
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Raimondi G, Glowacki AJ, et al. Bioinspired controlled release of CCL22 recruits regulatory T cells in vivo. Adv Mater. 2012;24(35):4735–4738.
   PubMed Web of Science ®Google Scholar
• Stephan MT, Stephan SB, Bak P, et al. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials. 2012;33(23):5776–5787.
   PubMed Web of Science ®Google Scholar
• Stephan MT, Moon JJ, Um SH, et al. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010;16(9):1035.
   PubMed Web of Science ®Google Scholar
• Steenblock ER, Fahmy TM. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther. 2008;16(4):765–772.
   PubMed Web of Science ®Google Scholar
• Oelke M, Maus MV, Didiano D, et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells. Nat Med. 2003;9(5):619.
   PubMed Web of Science ®Google Scholar
• Steenblock ER, Fadel T, Labowsky M, et al. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. J Biol Chem. 2011;286(40):34883–34892.
   PubMed Web of Science ®Google Scholar
• Labowsky M, Fahmy T. Effect of cell surface deformation on synaptic factor accumulation during the early stages of T cell activation. Chem Eng Sci. 2013;90:275–283.
   Web of Science ®Google Scholar
• Labowsky M, Fahmy T. Diffusive transfer between two intensely interacting cells with limited surface kinetics. Chem Eng Sci. 2012;74:114–123.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–1822.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev. 2013;65(1):104–120.
   PubMed Web of Science ®Google Scholar
• Verma RK, Garg S. Drug delivery technologies and future directions. Pharm Technol. 2001;25(2):1–14.
   Google Scholar
• Venkatpurwar V, Rhodes S, Oien K, et al. Drug-not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano-and micro-particles: size does not matter. Toxicology. 2015;330:9–18.
   PubMed Web of Science ®Google Scholar
• Kojima R, Yoshida T, Tasaki H, et al. Release mechanisms of tacrolimus-loaded PLGA and PLA microspheres and immunosuppressive effects of the microspheres in a rat heart transplantation model. Int J Pharm. 2015;492(1–2):20–27.
   PubMedGoogle Scholar
• Bryant J, Hlavaty KA, Zhang X, et al. Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials. 2014;35(31):8887–8894.
   PubMed Web of Science ®Google Scholar
• Solhjou Z, Uehara M, Bahmani B, et al. Novel application of localized nanodelivery of anti–interleukin‐6 protects organ transplant from ischemia–reperfusion injuries. Am J Transplant. 2017;17(9):2326–2337.
   PubMed Web of Science ®Google Scholar
• Uehara M, Bahmani B, Jiang L, et al. Nanodelivery of mycophenolate mofetil to the organ improves transplant vasculopathy. ACS Nano. 2019;13(11):12393–12407.
   PubMed Web of Science ®Google Scholar
• Lewis JS, Roche C, Zhang Y, et al. Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres. J Mat Chem B. 2014;2(17):2562–2574.
   PubMed Web of Science ®Google Scholar
• Tasciotti E, Cabrera FJ, Evangelopoulos M, et al. The emerging role of nanotechnology in cell and organ transplantation. Transplantation. 2016;100(8):1629.
   PubMed Web of Science ®Google Scholar
• Farina M, Alexander JF, Thekkedath U, et al. Cell encapsulation: overcoming barriers in cell transplantation in diabetes and beyond. Adv Drug Deliv Rev. 2019;139:92–115.
   PubMed Web of Science ®Google Scholar
• Li J, Yue S, Zhao Q, et al. Glucose cntrol in islet transplanted mice using long acting liraglutide nanoparticles. Nanosci Nanotechnol Lett. 2019;11(3):398–405.
   Google Scholar
• Mistry NP, Desai JL, Thakkar HP. Formulation and evaluation of tacrolimus‐loaded galactosylated Poly (lactic‐co‐glycolic acid) nanoparticles for liver targeting. J Pharm Pharmacol. 2015;67(10):1337–1348.
   PubMed Web of Science ®Google Scholar
• Zamorano-Leon JJ, Hernandez-Fisac I, Guerrero S, et al. New strategy of tacrolimus administration in animal model based on tacrolimus-loaded microspheres. Transpl Immunol. 2016;36:9–13.
   PubMed Web of Science ®Google Scholar
• Italia J, Bhatt D, Bhardwaj V, et al. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®. J Control Release. 2007;119(2):197–206.
   PubMed Web of Science ®Google Scholar
• Kapoor DN, Bhatia A, Kaur R, et al. PLGA: a unique polymer for drug delivery. Ther Deliv. 2015;6(1):41–58.
   PubMed Web of Science ®Google Scholar
• Sharma S, Parmar A, Kori S, et al. PLGA-based nanoparticles: a new paradigm in biomedical applications. Trends Analyt Chem. 2016;80:30–40.
   Web of Science ®Google Scholar
• Houchin M, Topp E. Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms. J Pharm Sci. 2008;97(7):2395–2404.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain A, Gulbake A, et al. Peptide and protein delivery using new drug delivery systems. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2013;30(4):293–329.
   Web of Science ®Google Scholar
• Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17(3):247–289.
   PubMed Web of Science ®Google Scholar
• Biondi M, Ungaro F, Quaglia F, et al. Controlled drug delivery in tissue engineering. Adv Drug Deliv Rev. 2008;60(2):229–242.
   PubMed Web of Science ®Google Scholar
• Ballestrero A, Boy D, Moran E, et al. Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev. 2008;60(2):173–183.
   PubMed Web of Science ®Google Scholar
• Sah H. Protein behavior at the water/methylene chloride interface. J Pharm Sci. 1999;88(12):1320–1325.
   PubMed Web of Science ®Google Scholar
• Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001;22(5):405–417.
   PubMed Web of Science ®Google Scholar
• Vasita R, Shanmugam K, Katti DS. Degradation behavior of electrospun microfibers of blends of poly (lactide-co-glycolide) and Pluronic® F-108. Polym Degrad Stab. 2010;95(9):1605–1613.
   Web of Science ®Google Scholar
• Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135–146.
   PubMed Web of Science ®Google Scholar
• Tabatabaei Mirakabad FS, Nejati-Koshki K, Akbarzadeh A, et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15(2):517–535.
   PubMedGoogle Scholar
• Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887–913.
   Web of Science ®Google Scholar
• Sah H, Thoma LA, Desu HR, et al. Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomedicine. 2013;8:747.
   PubMed Web of Science ®Google Scholar
• Fredenberg S, Wahlgren M, Reslow M, et al. The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems—a review. Int J Pharm. 2011;415(1–2):34–52.
   PubMed Web of Science ®Google Scholar